Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Akoya Biosciences ( (AKYA) ) has issued an update.
On July 8, 2025, Akoya Biosciences, a company involved in a merger, repaid all outstanding obligations under its Credit Agreement and terminated its Employee Stock Purchase Plan and Equity Distribution Agreement. The merger resulted in the conversion of Akoya’s common stock into Quanterix shares and cash, adjustments to stock options and restricted stock units, and significant changes in Akoya’s board and executive officers. Akoya also requested the suspension of its stock trading on Nasdaq and plans to terminate its stock registration and reporting obligations.
The most recent analyst rating on (AKYA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Akoya Biosciences stock, see the AKYA Stock Forecast page.
Spark’s Take on AKYA Stock
According to Spark, TipRanks’ AI Analyst, AKYA is a Neutral.
Akoya Biosciences faces substantial financial hurdles with persistent losses and high leverage, significantly impacting the overall score. While short-term technical indicators show some positive momentum, long-term trends remain bearish. The amended merger agreement with Quanterix is a potential positive catalyst, but the negative P/E ratio limits valuation attractiveness.
To see Spark’s full report on AKYA stock, click here.
More about Akoya Biosciences
Average Trading Volume: 582,355
Technical Sentiment Signal: Sell
Current Market Cap: $64.44M
See more insights into AKYA stock on TipRanks’ Stock Analysis page.